162 Views

VC-backed Xactly files for IPO

San Jose, Calif.-based Xactly, a provider of sales performance management solutions, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. J.P. Morgan Securities LLC and Deutsche Bank AG Securities Inc will serve as the lead underwriters. The company’s backers include Alloy Ventures, Bay Partners, Glynn Capital Management, Outlook Ventures and Rembrandt Ventures.

101 Views

Fortress-owned FTAI debuts IPO

Fortress Transportation and Infrastructure Investors LLC, which owns and acquires transportation-related infrastructure and equipment, has raised $34 million for its IPO after pricing its 20 million shares at $17 per share. The stock began trading Friday on the NYSE under the ticker symbol “FTAI.” Citigroup Global Markets Inc., BofA Merrill Lynch, Barclays Capital Inc, Deutsche Bank Securities Inc and UBS Securities LLC are the lead underwriters. FTAI is owned by Fortress Investment Group.

VC-backed Arcadia Biosciences goes public

Davis, California-based Arcadia Biosciences, an agricultural products developer, has raised $65.6 million for its IPO after pricing its 8.2 million shares at $8 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “RKDA.” Credit Suisse Securities (USA) LLC and J.P. Morgan Securities LLC are the lead underwriters. Arcadia’s backers include Mandala Capital Limited, CMEA Capital, BASF Venture Capital and Saints Capital.

VC-backed Nivalis files for IPO

Boulder, Colorado-based Nivalis Therapeutics, a developer of drugs for patients with cystic fibrosis, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. Nivalis plans on trading the stock on the NASDAQ under the ticker symbol “NVLS.” Cowen and Company and Stifel are serving as lead underwriters. The company’s backers include Apple Tree Partners, Deerfield, RA Capital, Rock Springs Capital and Wellington Management.

140 Views

VC-backed Glaukos Corp files for IPO

Laguna Hills, California-based Glaukos Corporation, a developer of treatments for glaucoma, has filed for an IPO. The number of shares that will be sold as well as the IPO’s pricing terms have yet to be set. The company plans on trading the stock on the NYSE under the ticker symbol “GKOS.” J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co are serving as the lead underwriters. Glaukos’ backers include OrbiMed Advisors, Frazier Healthcare Ventures, InterWest Partners, Domain Associates, Fjord Ventures, Montreaux Equity Partners and Versant Ventures

140 Views

VC-backed Shopify sets IPO pricing terms

Canada-based Shopify Inc, a commerce platform for small and medium-sized businesses, has priced its IPO of 7.7 million shares at between $12 and $14 per share. The company will list the stock on the New York Stock Exchange and the Toronto Stock Exchange under the ticker symbols “SHOP” and “SH” respectively. Morgan Stanley, Credit Suisse and RBC Capital Markets are serving as the lead underwriters. Shopify’s backers include OMERS Ventures, Insight Venture Partners, Bessemer Venture Partners, FirstMark Capital, Georgian Partners and Felicis Ventures.

VC-backed aTyr Pharma rolls out IPO

San Diego-based biotherapeutics company aTyr Pharma Inc has debuted its IPO after pricing its 5.36 million shares at $14 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “LIFE.” J.P. Morgan Securities LLC and Citigroup Global Markets are serving as the lead underwriters. The company’s backers include Alta Partners, Cardinal Partners, Domain Associates, Polaris Partners, Sofinnova Ventures, T. Rowe Price Associates Inc, Federated Investors Inc, Deerfield, Rock Springs Capital Management, EcoR1 Capital and Sphera Global Healthcare.

VC-backed CoLucid goes public

Durham, North Carolina-based CoLucid Pharmaceuticals, which develops oral lasmiditan that treats migraine headaches, has raised $55 million for its IPO after pricing its 5.5 million shares at $10 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “CLCD.” Piper Jaffray & Co. and Stifel are serving as the lead underwriters. CoLucid’s backers include TVM Capital Life Science, Novo Ventures, Auriga Partners, Pappas Ventures, Domain Associates, Care Capital, Triathlon Medical Ventures and Pearl Street Ventures.

VC-backed Adaptimmune rolls out IPO

UK and Philadelphia-based biotechnology company Adaptimmune Therapeutics plc has debuted its IPO after pricing its 11.25 million shares at $17 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “ADAP.” BofA Merrill Lynch, Cowen and Company and Leerink Partners LLC are serving as the lead underwriters. Adaptimmune’s backers include New Enterprise Associates, OrbiMed Advisors, Wellington Management Company, Fidelity Biosciences, Foresite Capital Management, Ridgeback Capital Management and Rock Springs Capital.

153 Views

SunGard hires banks for potential IPO: Reuters

SunGard Data Systems Inc has hired investment banks for a potential initial public offering that could value the financial technology company at as much as $10 billion, including debt, Reuters News reported.

PE HUB Community

Join the 12518 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget